Morningstar21d
United States FDA Approves NM8074 (Ruxoprubart) IND for Treating Dermatomyositis (DM): A Chronic Inflammatory Disorder of the Skin
Dermatomyositis (DM ... This disease is characterized by debilitating muscle weakness and distinctive skin rashes. Notably, about half of those affected experience falls, and one-third require ...
Yahoo Finance21d
United States FDA Approves NM8074 (Ruxoprubart) IND for Treating Dermatomyositis (DM): A Chronic Inflammatory Disorder of the Skin
The United States FDA Approves the Initiation for Phase II Efficacy Trial in Dermatomyositis (DM) Patients: A Skin & Muscle Disorder CLEVELAND, Feb. 24, 2025 (GLOBE NEWSWIRE) -- NovelMed ...